U.S. markets closed
  • S&P 500

    3,465.39
    +11.90 (+0.34%)
     
  • Dow 30

    28,335.57
    -28.09 (-0.10%)
     
  • Nasdaq

    11,548.28
    +42.28 (+0.37%)
     
  • Russell 2000

    1,640.50
    +10.25 (+0.63%)
     
  • Crude Oil

    39.78
    -0.86 (-2.12%)
     
  • Gold

    1,903.40
    -1.20 (-0.06%)
     
  • Silver

    24.70
    -0.01 (-0.04%)
     
  • EUR/USD

    1.1868
    +0.0042 (+0.36%)
     
  • 10-Yr Bond

    0.8410
    -0.0070 (-0.83%)
     
  • GBP/USD

    1.3038
    -0.0042 (-0.32%)
     
  • USD/JPY

    104.7200
    -0.1200 (-0.11%)
     
  • BTC-USD

    13,290.73
    -21.40 (-0.16%)
     
  • CMC Crypto 200

    260.05
    -1.40 (-0.54%)
     
  • FTSE 100

    5,860.28
    +74.63 (+1.29%)
     
  • Nikkei 225

    23,516.59
    +42.32 (+0.18%)
     

Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

Zacks Equity Research
·4 mins read

Novo Nordisk A/S NVO reported fourth-quarter 2019 earnings of 55 cents per American Depositary Receipt (ADR), matching the Zacks Consensus Estimate and increasing 5% in DKK from the year-ago quarter.

Revenues grew 9% year over year in DKK (up 6% at constant exchange rate [CER]) to $4.86 billion. Revenues   beat the Zacks Consensus Estimate of $4.83 billion.

In the past year, Novo Nordisk’s shares have rallied 26.5%, outperforming the industry’s growth of 11.7%.

 All growth rates mentioned below are on a year-over-year basis.

Quarter in Detail

Novo Nordisk operates in two segments — Diabetes and Obesity care, and Biopharmaceuticals.

The Diabetes and Obesity Care segment sales grew 7% at CER. Sales of insulin decreased 4% at CER to DKK 14,907 million. Sales of long-acting insulin (Tresiba, Xultophy and Levemir) declined 9% to DKK 5,102 million.

Sales at the Biopharmaceuticals segment rose 2% at CER to DKK 5,087 million. Hemophilia sales were up 1% to DKK 2,554 million.

Ozempic had a strong launch and recorded sales of DKK 4,365 million in the quarter.

Research and development (R&D) expenses declined 5% at CER, owing to the priority review voucher for Rybelsus in the fourth quarter of 2018.

Administrative costs decreased 3% at CER from the year-ago period.

Sales and distribution costs ascended 8% at CER, owing to resource allocation to the growth markets, promotional activities for Saxenda, launch activities for Ozempic and prelaunch activities for Tresiba in China.

Full-Year 2019 Update

The company recorded earnings of $2.46 for 2019, up 3% in DKK.

The company recorded sales of $18.3 billion, up 9% in DKK and 6% at CER

Other Updates

In January 2020, Ozempic was approved in the United States for cardiovascular (CV) risk reduction in people with Type II diabetes and established cardiovascular diseases. Rybelsus’ label in the United States was updated with additional information from the PIONEER 6 CV outcomes study. In the same month, Rybelsus was recommended for approval for the treatment of adults with Type II diabetes by the European regulatory authorities.

2020 Outlook

Novo Nordisk expects 3-6% sales growth at CER for 2020. This reflects a strong performance for the GLP-1-based diabetes care products Ozempic, Victoza and Rybelsus, the obesity care product Saxenda, the portfolio of new-generation insulin and the contribution from biopharm products Esperoct, Refixia and NovoEight.

However, this is expected to be partly offset by intensifying global competition within the Diabetes Care and Biopharmaceuticals segments, especially for hemophilia inhibitor.

Persistent pricing pressure within Diabetes Care, especially in the United States, might also negatively impact sales.

Our Take

Continued growth from Victoza and Tresiba, the strong launch of Ozempic and higher contributions from Saxenda should offset the impact of lower realized prices in the United States, loss of exclusivity for products in hormone replacement therapy and stiff rivalry within diabetes and biopharmaceuticals markets.

 

Novo Nordisk A/S Price, Consensus and EPS Surprise

 

Novo Nordisk A/S Price, Consensus and EPS Surprise
Novo Nordisk A/S Price, Consensus and EPS Surprise

Novo Nordisk A/S price-consensus-eps-surprise-chart | Novo Nordisk A/S Quote

Zacks Rank & Stocks to Consider

Novo Nordisk currently has a Zacks Rank #4 (Sell).

A few better-ranked stocks from the healthcare space are Pfizer, Inc. PFE, Sanofi SNY and Roche Holding AG RHHBY. While Pfizer sports a Zacks Rank #1 (Strong Buy), Sanofi and Roche carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Pfizer’s earnings per share estimates have moved up from $2.62 to $2.77 for 2020 and from $2.73 to $2.81 for 2021 in the past 90 days. The company delivered a positive earnings surprise of 7.46%, on average, in three of the last four quarters.

Sanofi’s earnings per share estimates have moved up from $3.26 to $3.29 for 2019 and from $3.45 to $3.49 for 2020 in the past 60 days. The company delivered a positive earnings surprise of 8.25%, on average, in the last four quarters.

Roche’s earnings per share estimates have increased from $2.61 to $2.66 for 2020 and from $2.82 to $2.85 for 2021 in the past 60 days.

Biggest Tech Breakthrough in a Generation

Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity. A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.

See 8 breakthrough stocks now>>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
Novo Nordisk A/S (NVO) : Free Stock Analysis Report
 
Roche Holding AG (RHHBY) : Free Stock Analysis Report
 
Sanofi (SNY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research